UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
BIOTECHNOLOGY

BioNTech

B

BioNTech

BiotechnologyMainz, Germany
Visit Website

About BioNTech

BioNTech became a household name after co-developing one of the world's first authorised mRNA COVID-19 vaccines, demonstrating at global scale that mRNA technology could be translated from research concept into a licensed medicine in record time.

mRNA Platform and Oncology Pipeline

Founded in 2008 and headquartered in Mainz, Germany, BioNTech was built on the scientific conviction that mRNA could be engineered to instruct the body's own cells to produce therapeutically relevant proteins. While the COVID-19 vaccine (developed with Pfizer under the Comirnaty brand) brought the company to international prominence, BioNTech's founding ambition was in oncology. The company operates one of the most advanced individualised cancer vaccine programmes in the industry, designing patient-specific neoantigen treatments intended to train the immune system to recognise and attack tumour cells.

The broader pipeline spans several modalities, including cancer immunotherapies, next-generation mRNA vaccines for infectious diseases, and cell therapies. BioNTech has established partnerships with major pharmaceutical companies and academic institutions across Europe, North America, and Asia, with clinical operations and research sites in Germany, the United States, and the United Kingdom.

Global Reach and Listed Status

BioNTech is listed on the Nasdaq stock exchange under the ticker BNTX, having completed its initial public offering in October 2019. The company employs thousands of scientists, clinicians, and operational staff across its global network and maintains dedicated manufacturing facilities in Germany alongside contract manufacturing partnerships. Its African expansion programme, focused on building local mRNA manufacturing capacity, reflects a stated commitment to equitable vaccine access in lower-income markets.

In the B2B context, BioNTech engages with contract manufacturers, clinical research organisations, regulatory consultancies, and supply chain partners across the full drug development and commercialisation lifecycle.

Further information is available at biontech.com.

Similar Companies

More in Biotechnology

A

AN2 Therapeutics

Grounded in a proprietary boron chemistry platform, AN2 Therapeutics is a clinical-stage biopharmaceutical company advancing novel small-molecule therapeutics for rare, chronic, and serious infectious diseases. The company's approach centres on translating boron chemistry into candidates that address critical unmet needs across multiple therapy areas, targeting patients where existing treatment options remain inadequate. The development pipeline spans haematologic diseases, infectious diseases and oncology, with additional early-stage research programmes directed at oncology targets, bone disorders, and infectious disease. This breadth reflects the versatility of the underlying chemistry platform and the company's stated commitment to delivering high-impact medicines. AN2 Therapeutics is led by Co-Founder, President and Chief Executive Officer Eric Easom, who brings over 35 years of leadership experience in the biotechnology and pharmaceutical industry. A significant portion of that career, spanning more than two decades, has been focused on addressing unmet needs in infectious diseases, particularly those affecting the developing world. The leadership team also includes Michael R.K. (Dickon) Alley, Ph.D. as SVP Research Fellow and Head of Biology, Sanjay Chanda, Ph.D. as Chief Development Officer, Lucy O. Day as Chief Financial Officer, Josh Eizen as Chief Legal Officer and Chief Operating Officer, and Vince Hernandez as Senior Vice President of Research and Head of Chemistry. Further information is available at an2therapeutics.com.

View profile
A

Alkahest

Mining what it describes as the deepest layers of plasma knowledge, Alkahest combines artificial intelligence, multiomics analysis and real-world data with deep plasma protein expertise to drive drug discovery. A subsidiary of Grifols, the California-based research company focuses on identifying and developing transformative therapies derived from the science of plasma. The scientific foundation underlying Alkahest's pipeline rests on the premise that the plasma proteome is in constant flux, influencing human biology in ways that can both sustain and undermine health. According to the company, alterations in plasma protein concentration and conformation are linked to multiple drivers of disease, with changes appearing years before clinical diagnosis. This positions plasma proteins as potential early biomarkers capable of informing prediction, diagnosis and treatment. A significant competitive asset is access to Grifols' plasma repository, which the company describes as one of the world's largest collections, comprising more than 100 million plasma samples gathered over nearly 15 years. The dataset spans thousands of disease states and is linked to real-world health records. Alkahest applies advanced analytical and integrative multiomics capabilities to this resource to build an evolving picture of the protein network and its relationship to human ageing and disease. The company's work sits at the intersection of plasma biology, data science and therapeutic development, representing a scientifically grounded approach to conditions where conventional small-molecule or antibody strategies have faced limitations. Further information is available at alkahest.com.

View profile
A

AMO Pharma

AMO Pharma is building a portfolio of new medicines targeting serious and debilitating diseases, with a particular focus on rare and orphan genetic disorders. The privately held emerging biopharmaceutical company, headquartered in London, identifies and advances promising therapies for patient populations facing significant unmet need, guided by the principle that clinical development should deliver measurable value to patients at every stage of the journey. The pipeline reflects that commitment. AMO Pharma is progressing multiple candidates, including AMO-01, AMO-02, and AMO-04, across conditions that include Phelan-McDermid Syndrome, Rett Syndrome, and congenital myotonic dystrophy. The REACH-CDM pivotal clinical trial for congenital myotonic dystrophy represents a significant milestone in the company's development programme. Each indication falls within the rare or orphan disease space, where AMO Pharma's strategy is to identify assets with high potential impact and advance them through all phases of development, from early research through to potential approval. The company is led by a team of seasoned industry professionals who bring extensive experience in biomedical science, research, and asset acquisition across all phases of pharmaceutical development. This experienced leadership team combines deep scientific knowledge with commercial expertise, enabling a disciplined approach to candidate selection and clinical execution. AMO Pharma also maintains an active partnerships function, reflecting a business model that combines internal expertise with external collaboration to move treatments forward for underserved patient communities. Further information is available at amo-pharma.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy